ERBB2 and breast carcinoma: Neratinib is an irreversible pan-HER family TKI that has been approved for the treatment of early-stage HER2+ breast cancer following adjuvant trastuzumab, and in combination with capecitabine for the treatment of metastatic HER2+ breast cancer after at least two prior HER2-targeted therapies [10,11].